MULTI-001 Nivolumab v6
MULTI-002 Carboplatin and etoposide v1
MULTI-003 Pembrolizumab v7
MULTI-004 Atezolizumab v6
MULTI-018 Larotrectinib v1
MULTI-019 Entrectinib v1
LUN-006 Pemetrexed v8
LUN-007 Cisplatin & Pemetrexed v8
LUN-024 Carboplatin & Pemetrexed v6
LUN-027 Crizotinib for ALK positive advanced NSCLC v5
LUN-029 Nintendanib (Vargatef) and Docetaxel for NSCLC v3
LUN-030 Ceritinib v2
LUN-031 Osimertinib v2
LUN-032 Pembrolizumab for previously treated metastatic NSCLC v2
LUN-034 Alectinib v2
LUN-035 Durvalumab v3
LUN-036 Pembrolizumab, Carboplatin & Pemetrexed followed by Maintenance Pembrolizumab and Pemetrexed v1 LUN-037 Pembrolizumab, Cisplatin & Pemetrexed followed by Maintenance Pembrolizumab and Pemetrexed v1
LUN-038 Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (EAMs scheme) v1
LUN-039 Brigatinib v1
LUN-040 Weekly paclitaxel and carboplatin concurrent with radiotherapy followed by 3 weekly paclitaxel and carboplatin consolidation v1
LUN-042 Dacomitinib v1
LUN-043 Pembrolizumab, carboplatin and paclitaxel v1
LUN-044 Lorlatinib v1
LUN-045 Nivolumab and Ipilimumab for mesothelioma (EAMs) v1
